Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial
- 3 August 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (1) , 185-190
Abstract
Background Mastocytosis is characterized by the accumulation and activation of mast cells in different organs, most commonly the skin. Miltefosine, a raft modulator, has recently been shown to inhibit the activation of mast cells and to reduce mast cell‐driven skin inflammatory responses. Objectives To study the safety and efficacy of topical miltefosine treatment of skin lesions in patients with mastocytosis. Methods Thirty‐nine adult patients with mastocytosis with skin involvement were treated in a double‐blind, placebo‐controlled, parallel trial with topical miltefosine and clobetasol for 2 weeks. Treatment areas were analysed for changes in skin lesions and symptoms following mechanical irritation using novel volumetric imaging techniques and quantitative histomorphometry. Results Miltefosine and clobetasol failed to reduce significantly weals and flare‐type skin responses following mechanical provocation. Miltefosine showed a trend towards reducing the volume of weals. Clobetasol significantly decreased the volume of weals and the number of mast cells in the upper dermis. Treatment with miltefosine, but not with clobetasol, was often associated with eczematous skin irritation, which may, at least in part, be related to the formulation of miltefosine containing the potentially irritating alkanol propanediol as the vehicle. Conclusions Raft modulators such as miltefosine are promising candidates for novel therapeutic strategies in patients with cutaneous mastocytosis. Future studies should be performed with improved formulations using nonirritant vehicles.Keywords
This publication has 13 references indexed in Scilit:
- Miltefosine Inhibits Human Mast Cell Activation and Mediator Release Both In Vitro and In VivoJournal of Investigative Dermatology, 2009
- Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cellsBiochemical Pharmacology, 2007
- A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cellsMolecular Cancer Therapeutics, 2007
- FcϵRI and Thy-1 domains have unique protein and lipid compositionsJournal of Lipid Research, 2007
- Mastocytosis: State of the ArtPathobiology, 2007
- Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in MastocytosisInflammation & Allergy - Drug Targets, 2006
- Pattern analysis of human cutaneous mast cell populations by total body surface mappingBritish Journal of Dermatology, 2003
- FcϵRI as a paradigm for a lipid raft-dependent receptor in hematopoietic cellsSeminars in Immunology, 2001
- Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems.Journal of Clinical Investigation, 1997
- A survey of the number and distribution of mast cells in the skin of patients with mast cell disordersJournal of Allergy and Clinical Immunology, 1988